Atrial Fibrillation Genetics Update: Toward Clinical Implementation.

Kalstø SM1, Siland JE2, Rienstra M2, Christophersen IE1,3.

Author information

1: Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Rud, Norway.
2: Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
3: The Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.

Abstract

Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide and may have serious cardiovascular health consequences. AF is associated with increased risk of stroke, dementia, heart failure, and death. There are several known robust, clinical risk predictors for AF, such as male sex, increasing age, and hypertension; however, during the last couple of decades, a substantive genetic component has also been established. Over the last 10 years, the discovery of novel AF-related genetic variants has accelerated, increasing our understanding of mechanisms behind AF. Current studies are focusing on mapping the polygenic structure of AF, improving risk prediction, therapeutic development, and patient-specific management. Nevertheless, it is still difficult for clinicians to interpret the role of genetics in AF prediction and management. Here, we provide an overview of relevant topics within the genetics of AF and attempt to provide some guidance on how to interpret genetic advances and their implementation into clinical decision-making.

KEYWORDS:

atrial fibrillation; genetics; genome-wide association studies (GWAS); heritability; personalized medicine; precision medicine; risk factors; whole genome sequencing